SNESBasic Materials · Specialty ChemicalsThe 1 Wall Street analysts covering SenesTech, Inc. hold a median 12-month price target of $6.75 — +720.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 23 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores SenesTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Value (10): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SNES, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +720.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | $3.50 → $10 |
| 12 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | $3.50 → $10 |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Dec 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 May 2023 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 18 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 20 Jan 2021 | HC Wainwright & Co. | Initiates | Buy | $4.00 |
| 25 Nov 2020 | Craig-Hallum | Initiates | Buy | — |
| 4 Jan 2017 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SNES appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, SenesTech, Inc. returned −77.9% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 54% of US stocks
Cheaper than 78% of US stocks
Cheaper than 64% of US stocks
Higher than 72% of US stocks
Higher than 61% of US stocks
Higher than 86% of US stocks
Higher than 10% of US stocks
Higher than 1% of US stocks
Higher than 12% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SenesTech, Inc. has a market value of $4.3M and an enterprise value of $1.8M.
Revenue in the twelve months to 30 June 2026: $2.4M. The latest quarter grew 23.2% year on year.
Net income over the same four quarters: −$7.0M, a −294.7% net margin.
Diluted earnings per share, trailing twelve months: $−1.37.
Free cash flow in the twelve months to 30 June 2026: −$6.7M.
Trailing P/E: 0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
SenesTech, Inc. employs 23 people — $103K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SenesTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SenesTech said Nasdaq notified it on Oct. 20 that its closing bid price had remained below $1.00 for 30 consecutive business days, so it does not currently meet the exchange’s minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Why it matters — The notice concerns SNES’s compliance with a Nasdaq continued-listing requirement.
Glenbrook Capital Management, a long-time SenesTech shareholder, said it owns over 30% of the company’s outstanding shares and issued a letter. It said a better market strategy and sharper capitalization focus would create significant upside.
Why it matters — Glenbrook’s ownership stake and stated views on SenesTech’s strategy and capitalization may be relevant to shareholders tracking the company.
SenesTech reported an 88% reduction in rat activity in its Chicago Wicker Park Bucktown pilot. Rodent-related 311 calls in the deployment area fell 36% while citywide calls increased, and Evolve expanded to six Chicago-area SSAs and wards.
Why it matters — The reported pilot results and expansion provide SNES watchers with updates on product performance and deployment reach.
SenesTech reported preliminary third-quarter 2026 revenue of $1.1 million, a company quarterly record and 40% growth from the prior quarter.
Why it matters — The preliminary results give SNES watchers an update on quarterly revenue growth and the company’s highest reported quarterly revenue to date.
SenesTech announced that its Evolve® rodent birth control products will soon be available through Grove Collaborative's online marketplace, expanding the company's third-party e-commerce distribution to sustainability-focused consumers.
Why it matters — This expansion broadens SenesTech's retail reach and introduces its products to a new audience that aligns with its sustainable rodent management positioning, potentially growing sales channels for SNES watchers.
The 1 Wall Street analysts covering SenesTech, Inc. have a median 12-month price target of $6.75, with estimates ranging from $3.5 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering SenesTech, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SenesTech, Inc. 37 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Oct 2026, SenesTech, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +720.1% from the last close, and Ticker Nerd's factor model ranks SenesTech, Inc. 37 out of 100 as at 23 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SenesTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNES are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $10 over the next 12 months.
SenesTech, Inc. returned -77.9% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
SenesTech, Inc. is a biotechnology company focused on fertility-based pest management for rats and mice.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "SenesTech Receives Nasdaq Minimum Bid Price Notification and Highlights Record Third Quarter Revenue". SenesTech said Nasdaq notified it on Oct. 20 that its closing bid price had remained below $1.00 for 30 consecutive business days, so it does not currently meet the exchange’s minimum bid price requirement for continued listing on the Nasdaq Capital Market.
SenesTech, Inc. is a biotechnology company focused on fertility-based pest management for rats and mice. The company develops and commercializes non-lethal rodent control products designed to reduce reproduction and help manage animal pest populations. Its current product line includes ContraPest, a liquid bait used for rat population control, Evolve, a soft bait for rats, and Evolve Mouse, a bait formulation for mice. SenesTech also provides teleconsulting and technical advisory services to support pest management programs. The company’s solutions are used in commercial, agricultural, and urban settings where controlling rodent activity is important for sanitation, property protection, and operational reliability. Headquartered in Phoenix, Arizona, SenesTech positions fertility control as an alternative approach within the broader pest management market.
CEO Mr. Michael Edell · 23 employees · United States · https://www.senestech.com
